Captopril's effect on heart function in Duchenne muscular dystrophy
Intermediate Term Effect of Captopril on Left Ventricle Global Longitudinal Strain in Patients With Duchenne Myodystrophy
This study tests if adding the heart medication Captopril can improve heart function in kids and adults with Duchenne muscular dystrophy who have heart problems.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 6 Years and up |
| Sex | Male |
| Sponsor | Ain Shams University Academic / other |
| Locations | 1 site (Cairo) |
| Trial ID | NCT06485661 on ClinicalTrials.gov |
What this trial studies
This study investigates the impact of Captopril, an ACE inhibitor, as an additional treatment for patients with Duchenne muscular dystrophy (DMD) who have impaired left ventricular function. It aims to measure changes in heart function using Global Longitudinal Strain (GLS) over an intermediate term. The study focuses on genetically confirmed DMD patients aged 6 and older with specific heart function criteria. By assessing the effectiveness of Captopril, the research seeks to provide insights into managing cardiomyopathy associated with DMD.
Who should consider this trial
Good fit: Ideal candidates are genetically confirmed DMD patients aged 6 and older with abnormal GLS measurements.
Not a fit: Patients with contraindications to ACE inhibitors or significantly reduced heart function may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could improve heart function and overall health outcomes for patients with Duchenne muscular dystrophy.
How similar studies have performed: While the use of ACE inhibitors in cardiomyopathy has been explored, this specific application in DMD is relatively novel and not extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Genetically confirmed Duchenne myodystrophy (DMD) patients with abnormal GLS \< -18% with minimum age of 6 years old. Exclusion Criteria: * Any patient who refuses to sign an informed consent. * Contraindication to ACEI: hypersensitivity - renal impairment - bilateral renal artery stenosis - aortic valve stenosis - hyperkalemia - hypotension. * Reduced ejection fraction below 50%.
Where this trial is running
Cairo
- Ain Shams university — Cairo, Egypt (Recruiting)
Study contacts
- Principal investigator: Mona Mostafa Rayan, MD — Professor of cardiology -Ain Shams university
- Study coordinator: Fatma Ebeid, MD
- Email: dr.fatma_ebeid@yahoo.com
- Phone: 00201095569596
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.